Canadian Cancer Trials Group Bulletins

Trial Management Group


Permanent Trial Closure

Canadian Cancer Trials Group BR.25 - A Phase II Study of Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT)For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC) - has been permanently closed.

This trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. Any documentation submitted to Canadian Cancer Trials Group for this trial will be not be accepted and will be returned to sites. Please notify your REB of any outstanding ethics documents and of the final completion of this trial.

You can find a memo about this closure here ... https://www.ctg.queensu.ca/trials/permanent_closure/closure.html.

Any questions about this can be directed to Patti O'Brien, BR.25 Study Coordinator, at pobrien@ctg.queensu.ca or 613-533-6430.